National Brain Tumor Society applauds the passage of a bipartisan congressional resolution officially designating Wednesday, July 16, 2025, as the seventh annual Glioblastoma Awareness Day in the United States. This resolution reflects the continued commitment of lawmakers to raise public awareness of this highly aggressive and deadly form of brain cancer and honors those who’ve been impacted by glioblastoma, past and present.
This year’s resolution (S.Res.285) in the Senate was led by Senator Lindsey Graham (R-SC), with cosponsors including Sen. Ruben Gallego (D-AZ), Sen. Mark Kelly (D-AZ), Sen. Chris Coons (D-DE), Sen. Raphael Warnock (D-GA), Sen. Ed Markey (D-MA), Sen. Elizabeth Warren (D-MA), Sen. Chris Van Hollen (D-MD), Sen. Tim Scott (R-SC), and Sen. John Barrasso (R-WY).
A companion bill in the House of Representatives (H.Res.394) was led by Representative Roger Williams (R-TX), with cosponsors including Rep. Julia Brownley (D-CA), Rep. Brian Mast (R-FL), Rep. Nikki Budzinski (D-IL), Rep. Jan Schakowsky (D-IL), Rep. Eric Sorensen (D-IL), Rep. Jake Auchincloss (D-MA), Rep. Jamie Raskin (D-MD), Rep. Debbie Dingell (D-MI), Rep. Donald Davis (D-NC), Rep. Deborah Ross (D-NC), Rep. Suzanne Bonamici (D-OR), Rep. Chrissy Houlahan (D-PA), and Rep. Suzan DelBene (D-WA).
The following is a statement from David F. Arons, JD, president and chief executive officer of the National Brain Tumor Society (NBTS):
“As we recognize the seventh annual Glioblastoma Awareness Day, we pause to remember those who we’ve lost to this disease, support the individuals and families currently facing a diagnosis, and acknowledge the caregivers and medical professionals who confront the challenges of glioblastoma every day.
“Glioblastoma remains one of the most aggressive and complex cancers, with limited treatment options and survival rates that have remained largely unchanged. Yet, through the collective efforts of patients, advocates, and lawmakers, awareness is growing — and with it, the opportunity for meaningful progress.
This year’s resolution comes at a pivotal time as Congress has reintroduced the Bolstering Research and Innovation Now (BRAIN) Act (H.R.2767/S.1330) — a landmark, bipartisan piece of legislation developed specifically to address the unique needs of Americans living with brain tumors like glioblastoma, as well as the researchers and clinicians advancing their care. The BRAIN Act takes a comprehensive approach to improving outcomes, from basic scientific research and early-phase drug development to clinical trials, diagnostic innovation, treatment planning, and quality-of-life support. Its momentum is a clear signal that glioblastoma and other brain tumors are receiving the national attention they urgently deserve.
“As the largest patient advocacy non-profit solely dedicated to the brain tumor community, NBTS is deeply grateful to the bipartisan group of Senators and Representatives who continue to lead the charge on behalf of the brain tumor community. Their dedication gives hope to the more than 13,000 Americans living across the country who will be diagnosed with glioblastoma this year and the tens of thousands more living with other forms of brain cancer.
“On July 16, we ask all Americans to join us in honoring Glioblastoma Awareness Day. Visit braintumor.org and GBMawarenessDay.org to learn more, take action, and be part of the movement to defeat brain tumors once and for all.”
Read full text of the Senate resolution here.
The full House resolution can be found here.
About Glioblastoma
Glioblastoma is the most common malignant (cancerous) brain tumor, accounting for approximately half of all primary malignant brain tumors. These tumors are also the most aggressive, complex, difficult to treat, and deadly type of brain tumor. It’s estimated that more than 13,000 new cases of glioblastoma will be diagnosed in the United States in 2025, and that more than 10,000 individuals in the United States will succumb to their disease this year. The five-year survival rate for glioblastoma patients is only 7.1 percent, and the median length of survival is only 8 months. These rates have changed little during the past 30 years.
